指南与共识肾小球疾病急性肾损伤慢性肾脏病

ACR 2021、EULAR 2022和KDIGO 2021指南/建议提出的伴肾小球肾炎的抗中性粒细胞胞质抗体相关血管炎管理

Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations.
指南 / 共识 · Nephrol Dial Transplant · 2023-01-01

本文解读ACR 2021、EULAR 2022和KDIGO 2021发布的伴肾小球肾炎的抗中性粒细胞胞质抗体相关血管炎管理指南/建议,比较其异同并讨论支持理由。文章关注诱导缓解治疗、糖皮质激素与avacopan的使用以及维持缓解治疗,指出避免进展至终末期肾病是主要未满足需求,并识别知识缺口。

要点

  • ACR 2021、EULAR 2022和KDIGO 2021均发布了伴肾小球肾炎的AAV管理指南/建议。
  • 严重肾脏病患者的诱导缓解治疗、糖皮质激素与avacopan的使用及维持缓解治疗是相关变化重点。
  • 避免进展至终末期肾病是AAV管理的主要未满足需求,对发病率、医疗费用和死亡风险影响重大。

核心结论

  • 文章旨在展示AAV-GN管理进展、识别指南与建议之间的差异、讨论支持理由并识别可从额外研究中获益的知识缺口。
  • 所有文件均依据发布时可获得的循证标准治疗提供指导。

研究设计与样本

  • 指南/共识类文件:ACR 2021联合血管炎基金会发布,EULAR 2022发布,KDIGO 2021发布更新建议。

主要发现

  • 肾脏受累在显微镜下多血管炎和肉芽肿性多血管炎中尤为相关,在嗜酸性肉芽肿性多血管炎中较少见。
  • 过去10年AAV-GN管理在药物开发与变革方面持续受到关注。
  • 相关变化涉及严重肾脏病患者的诱导缓解治疗、糖皮质激素与avacopan的使用以及维持缓解治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Updated guidelines on the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) were released in 2021 by the American College of Rheumatology jointly with the Vasculitis Foundation and, subsequently, in 2022 by the European Alliance of Associations for Rheumatology. In addition, in 2021, the Kidney Disease: Improving Global Outcomes had released updated recommendations on the treatment of AAV with glomerulonephritis (AAV-GN). Kidney involvement is particularly relevant in microscopic polyangiitis and granulomatosis with polyangiitis, but is less frequent in eosinophilic granulomatosis with polyangiitis. The management of AAV-GN has been a focus for drug development and change over the past 10 years. Avoidance of progression to end-stage kidney disease (ESKD) or kidney failure is one of the main unmet needs in the management of AAV, with ESKD having a major impact on morbidity, health costs and mortality risk. Relevant changes in AAV-GN management are related to remission-induction treatment of patients with severe kidney disease, the use of glucocorticoids and avacopan, and remission-maintenance treatment. All the documents provide guidance in accordance with the evidence-based standard of care available at the time of their release. With our work we aim to (i) show the progress made and identify the differences between guidelines and recommendations, (ii) discuss the supporting rationale for those, and (iii) identify gaps in knowledge that could benefit from additional research and should be revised in subsequent updates.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Casal Moura M, Gauckler P, Anders HJ, et al. Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations. Nephrol Dial Transplant. 2023. PMID: 37164940. doi:10.1093/ndt/gfad090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。